S1b3inL1
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity.
For research use only. We do not sell to patients.
- CAS No.: 3027437-21-1
- Formula: C103H158N30O24S
- Molecular Weight:2232.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Chemical Information
-
CAS No. 3027437-21-1
-
Molecular Weight 2232.61
-
Formula C103H158N30O24S
-
Sequence
cyclo(Ac-Tyr-Arg-Arg-Pro-Arg-Glu-Gln-Ile-Ile-Ile-Gly-Ser-Leu-Trp-Val-Phe-Cys)-Gly-NH2
-
Sequence Shortening
cyclo(Ac-YRRPREQIIIGSLWVFC)G-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)